Entry Detail



General Information

Database ID:exR0087622
RNA Name:hsa-miR-1197
RNA Type:miRNA
Chromosome:chr14
Starnd:+
Coordinate:
Start Site(bp):101025620End Site(bp):101025640
External Links:hsa-miR-1197



Disease Information

Disease Name:Breast Cancer
Disease Category:Cancers
MeSH ID:D001943
Type:Neoplasms/Breast Neoplasms
Alias:Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast



Expression Detail

GEO ID:GSE101841
Description:Serum microRNA profile of Her2 positive metastatic breast cancer patients
Experimental Design:Trastuzumab therapy
Case Disease Type:Breast Cancer
Case Disease SubType:HER2 positive metastatic breast cancer
Case Sample:Breast Cancer Trastuzumab resistant
Control Sample:Trastuzumab sensitive
Number of Case:42
Number of Control:61
Number of Samples:103





Regulatory Relationship

mRNA targets:
Gene SymbolChromosomeStart Site(bp)End Site(bp)Strand
AKAP1
chr17
57085092
57121346
+
ATP6V0D1
chr16
67438014
67481181
-
CBL
chr11
119206298
119313926
+
CDT1
chr16
88803789
88809258
+
NADK
chr1
1751232
1780457
-
ORAI1
chr12
121626550
121642677
+
REEP4
chr8
22138020
22141951
-
SCD
chr10
100347233
100364826
+
TIMM13
chr19
2425625
2427586
-
TIMP2
chr17
78852977
78925387
-
WDR33
chr2
127701027
127811187
-
ZBTB5
chr9
37438102
37465450
-
miRNA targets:NA
circRNA targets:NA
lncRNA targets:
lncRNA SymbolChromosomeStart Site(bp)End Site(bp)Strand
AC016876.2
chr17
7581964
7584086
-
AC020978.7
chr16
68224713
68227734
+
NEAT1
chr11
65422774
65445540
+
OIP5-AS1
chr15
41283990
41309737
+
SNHG5
chr6
85650491
85678932
-
XIST
chrX
73820649
73852723
-
Display:



Experiment Detail

GEO ID:GSE101841
Sample Source:Blood
Source Fraction:Serum
Platform:GPL23138
Method:Microarray
Num of detected RNA Type:1
Num of detected RNAs of this Type:1808
Sample treatment protocol:NA
RNA Extract protocol:Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions.
RNA library preparation protocol:Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.



Reference

PMID:29691399
Title:A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients.
Author:Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E
Journal:Nat Commun. 2018 Apr 24;9(1):1614.
Description:MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.